Physician profile
Ada Ip
NPI 1932631983
$4,542.22
in general payments reported to CMS, 2019-2025
7 companies · $3,057 in 2025
The $3,057 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $161 · 2024: $1,324 · 2025: $3,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065 · Travel and Lodging: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.44 |
| Travel and Lodging | $1,316.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,453.11 | 2025 | Optis, Dragonfly Opstar, Supera |
| Shockwave Medical, INC | $1,033.53 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $418.19 | 2024-2025 | General - Therapies, Avvigo Guidance System |
| Medtronic, INC. | $223.67 | 2024 | Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.73 | 2022 | |
| Teleflex LLC | $154.18 | 2025 | Guideliner, Trapliner |
| Terumo Medical Corporation | $98.81 | 2024 | Glidesheath Slender |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Ip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.